Search research articles
Contact Us
Filters
Showing results (101-110 of 110) with videos related to
Page
of 11
Sort By:
You have reached the last page of results.
This site can display upto 110 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 2, 2026
Pembrolizumab Monotherapy in Sorafenib-Treated and Treatment-Naive Advanced Hepatocellular Carcinoma: Long-Term Follow-Up of Open-Label, Phase 2 KEYNOTE-224 Study
Richard S Finn, Masatoshi Kudo, Ivan Borbath, et al.
The Lancet. Oncology
|
June 8, 2018
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X Zhu, Richard S Finn, Julien Edeline, et al.
Journal of Cancer Research and Clinical Oncology
|
April 15, 2021
Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial
Osman Öcal, Kerstin Schütte, Juozas Kupčinskas, et al.
Elife
|
December 12, 2019
MouseBytes, an open-access high-throughput pipeline and database for rodent touchscreen-based cognitive assessment
Flavio H Beraldo, Daniel Palmer, Sara Memar, et al.
Journal of the National Cancer Institute
|
December 1, 2025
NQO1 as a predictor of response to adjuvant GemCap treatment for pancreatic cancer
Dylan Williams, Chandni Patel, Kate Murray, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 15, 2014
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study
Juan W Valle, Daniel Palmer, Richard Jackson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 19, 2021
Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer
Ayumi Hashimoto, Debashis Sarker, Vikash Reebye, et al.
Hepatology (Baltimore, Md.)
|
November 8, 2019
Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach
Guohong Han, Sarah Berhane, Hidenori Toyoda, et al.
The Lancet. Gastroenterology & Hepatology
|
December 15, 2022
Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial
Paula Ghaneh, Daniel Palmer, Silvia Cicconi, et al.
JAMA Oncology
|
October 22, 2016
Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma
Ashton A Connor, Robert E Denroche, Gun Ho Jang, et al.
Page
of 11
Search research articles
Search
Showing results (101-110 of 110) with videos related to
Sort By:
Page
of 11
You have reached the last page of results.
This site can display upto 110 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 2, 2026
Pembrolizumab Monotherapy in Sorafenib-Treated and Treatment-Naive Advanced Hepatocellular Carcinoma: Long-Term Follow-Up of Open-Label, Phase 2 KEYNOTE-224 Study
Richard S Finn, Masatoshi Kudo, Ivan Borbath, et al.
The Lancet. Oncology
|
June 8, 2018
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X Zhu, Richard S Finn, Julien Edeline, et al.
Journal of Cancer Research and Clinical Oncology
|
April 15, 2021
Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial
Osman Öcal, Kerstin Schütte, Juozas Kupčinskas, et al.
Elife
|
December 12, 2019
MouseBytes, an open-access high-throughput pipeline and database for rodent touchscreen-based cognitive assessment
Flavio H Beraldo, Daniel Palmer, Sara Memar, et al.
Journal of the National Cancer Institute
|
December 1, 2025
NQO1 as a predictor of response to adjuvant GemCap treatment for pancreatic cancer
Dylan Williams, Chandni Patel, Kate Murray, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 15, 2014
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study
Juan W Valle, Daniel Palmer, Richard Jackson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 19, 2021
Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer
Ayumi Hashimoto, Debashis Sarker, Vikash Reebye, et al.
Hepatology (Baltimore, Md.)
|
November 8, 2019
Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach
Guohong Han, Sarah Berhane, Hidenori Toyoda, et al.
The Lancet. Gastroenterology & Hepatology
|
December 15, 2022
Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial
Paula Ghaneh, Daniel Palmer, Silvia Cicconi, et al.
JAMA Oncology
|
October 22, 2016
Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma
Ashton A Connor, Robert E Denroche, Gun Ho Jang, et al.
Page
of 11